跳至主要内容
临床试验/NCT05923216
NCT05923216Enrolling By Invitation不适用

Induction of Sustained Unresponsiveness to Sesame Using High- and Low-dose Sesame Oral Immunotherapy - Evaluation of Efficacy and Safety

Medical University of Warsaw2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年3月24日最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
发起方
入组人数
40
试验地点
2
主要终点
Sustained unresponsiveness to a sesame protein after discontinuing oral immunotherapy for 4 weeks.

研究概览

简要总结

This is an experimental, interventional study, following on from a clinical trial comparing the efficacy and safety of oral immunotherapy with low and high doses of sesame protein, in which patient desensitisation was achieved (High and Low Dose Oral Sesame Immunotherapy - Comparison of Efficacy and Safety, NCT05158413).

The aim of this study is to assess a sustained unresponsiveness (SU) to sesame protein after at least 8 months of previously assigned high- or low-dose sesame OIT, followed by 4-week-allergen avoidance, and verified by an open oral food challenge (OOFC).

详细描述

Oral immunotherapy is considered the most effective treatment for food allergy. There are two main goals of food immunotherapy: achievement of desensitisation and sustained unresponsiveness.

Desensitisation involves achieving temporary tolerance of the allergenic food by the patient only during regular intake of the allergen. The most desirable effect of immunotherapy is to achieve sustained unresponsiveness, i.e. to maintain the absence of adverse symptoms to a given allergen after specific immunotherapy has been discontinued for a defined period of time.

The study is a continuation of a clinical trial NCT05158413 which was designed to compare the efficacy and safety of oral immunotherapy (OIT) with low or high doses of sesame protein (300 or 1200 mg, respectively) in children with a confirmed diagnosis of sesame allergy. The participants of current study will be recruited from patients who have accomplished their per-protocol participation in previous trial.

Patients will receive the same maintenance dose of sesame allergen, which was used in previous trial (300 or 1200 mg, respectively), for 32 weeks (+/-2 weeks). Then, OIT will be discontinued for 4 weeks with strict sesame avoidance. Subsequently, an open oral food challenge (OOFC) will be performed to assess the achievement of sustained unresponsiveness.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
4 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • patients who have accomplished their per-protocol participation in trial NCT
  • signed Informed Consent by parent/legal guardian and patient aged>16 years old
  • patient's/caregiver's cooperation with researcher

排除标准

  • severe asthma
  • uncontrolled mild/moderate asthma: forced expiratory volume at one second (FEV1)<80% (under 5 percentile), FEV1/forced vital capacity (FEV)<75% (under 5 percentile), hospitalization due to asthma exacerbation within last 12 months
  • current oral/sublingual/subcutaneous immunotherapy with another allergen
  • eosinophilic esophagitis
  • allergic reaction of 4th or higher grade according to the World Allergy Organisation Systemic Allergic Reaction Grading System during immunotherapy
  • a history of severe recurrent anaphylaxis episodes
  • chronic diseases requiring continous treatment, including heart disease, epilepsy, metabolic disease, diabetes
  • medication:
  • oral, daily steroid therapy exceeding 1 month within the last 12 months
  • at least two courses of oral steroid therapy (at least 7 days) within the last 12 months
  • oral steroid therapy longer than 7 days within the last 3 months
  • biological treatment
  • the need to constantly take antihistamines
  • therapy with b-blockers, angiotensin converting enzyme (ACE) inhibitors, calcium channel inhibitors
  • pregnancy
  • no consent to participate in the study
  • lack of patient cooperation

结局指标

主要结局

Sustained unresponsiveness to a sesame protein after discontinuing oral immunotherapy for 4 weeks.

时间窗: Up to 9 months after starting maintenance phase

Percentage of patients tolerating their maintenance dose of sesame protein after a 4-week break in immunotherapy

The highest tolerated dose of sesame protein after discontinuing oral immunotherapy for 4 weeks.

时间窗: Up to 9 months after starting maintenance phase

Sustained unresponsiveness assessed as the highest tolerated dose of sesame protein at oral food challenge.

次要结局

  • Adverse events(Up to 9 months after starting maintenance phase)
  • Laboratory data(Up to 9 months after starting maintenance phase)
  • Skin prick test (SPT)(Up to 9 months after starting maintenance phase)
  • Tolerance of a single dose of 4000 mg of sesame protein(Up to 9 months after starting maintenance phase)

研究者

发起方
Medical University of Warsaw
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验